Why agilon health’s latest earnings matter for investors

agilon health (AGL) moved into the spotlight after reporting second quarter results that shifted from a net loss to a profit, accompanied by higher full year revenue guidance for 2026.

The company’s earnings update on 5 August 2026 also drew attention to risks related to leadership changes and heavy reliance on a small number of payers, which could influence membership growth and the economics of key contracts.

agilon health’s latest earnings release landed alongside sharp price swings, with a 10.0% 1 day share price return on 6 August and a 76.12% 90 day share price return. However, the 3 year total shareholder return is down 79.58%, which points to strong recent momentum after a weak longer term experience for many holders.

If this earnings move has you rethinking your watchlist, it could be a useful moment to see what other healthcare focused growth stories look like through our screener of 43 healthcare AI stocks.

After agilon health’s sharp rebound and a return to profit, the central question now is straightforward: Has the stock already priced in the turnaround, or is the recent move just the opening act for further upside as valuation comes under closer scrutiny next?

Most Popular Narrative: 22.2% Overvalued

At a last close of $95.51 versus a narrative fair value of $78.14, agilon health is framed as priced above its modeled fundamentals using a 7.11% discount rate.

Strategic investments in advanced data analytics, AI-driven platforms, and enhanced burden-of-illness and quality assessment programs are improving the identification and management of high-risk patients, which should contribute to improved risk adjustment, better medical cost control, and higher net margins and earnings beginning in 2026.

Want to see what is sitting behind that valuation gap? The narrative leans heavily on future earnings, margin repair and a richer profit multiple. Curious which assumptions really move the fair value line?

Result: Fair Value of $78.14 (OVERVALUED)

However, agilon health still faces meaningful threats from payer concentration and leadership instability. These issues could pressure margins and weaken the current valuation narrative.

Another view on agilon health’s valuation

The earlier narrative framed agilon health as 22.2% overvalued based on an analyst fair value of $78.14. Yet on simple sales-based metrics, the stock looks very different. agilon health trades on a P/S of 0.3x versus 1.4x for the wider US Healthcare industry and 2.1x for peers, while the fair ratio is 0.4x. That gap points to a large discount on current revenue, even after the recent rebound. Which perspective do you think better reflects the risk you are willing to take?

Next Steps

The mix of risks and rewards around agilon health might feel finely balanced, so it helps to go straight to the underlying data and form your own judgment. To see how those concerns and potential upsides compare directly, take a look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond agilon health?

If agilon health has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match different risk levels and income goals.

• Target potential upside by scanning a focused list of screener containing 19 high quality undiscovered gems that many investors may not yet be watching closely.
• Prioritise resilience by reviewing 79 resilient stocks with low risk scores that score well on stability and downside protection.
• Strengthen your income and growth mix by weighing companies in the 8 dividend fortresses that pair higher yields with solid underlying businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.